Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients Sebastian Michels, MD, Andreas Hans Scheel, MD, Matthias Scheffler,

Slides:

Advertisements

Similar presentations

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Advertisements

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients Katharina König, PhD, Martin Peifer,

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing Klazien Matter-Walstra, PhD, Matthias.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy Deepa Rangachari, MD, Xiuning.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer Marcel Wiesweg, MD,

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Matthias Scheffler, MD, Michaela A

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Oliver Gautschi, MD, Julie Milia, PhD, Bastien Cabarrou,

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Erratum Journal of Thoracic Oncology

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification.

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone Spasenija Savic,

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

S768I Mutation in EGFR in Patients with Lung Cancer

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae Eiji Iwama, MD, PhD, Isamu Okamoto, MD, PhD, Hidetake Yabuuchi, MD, PhD,

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

European Lung Cancer Conference (ELCC) 2016 Organisation

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

RET Rearrangements in Lung Adenocarcinoma and Radiation

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients Sebastian Michels, MD, Andreas Hans Scheel, MD, Matthias Scheffler, MD, Anne Maria Schultheis, MD, Oliver Gautschi, MD, Franziska Aebersold, MD, Joachim Diebold, MD, Georg Pall, MD, Sacha Rothschild, MD, PhD, Lukas Bubendorf, MD, Wolfgang Hartmann, MD, Lukas Heukamp, MD, Hans-Ulrich Schildhaus, MD, Jana Fassunke, PhD, Michaela Angelika Ihle, PhD, Helen Künstlinger, Carina Heydt, PhD, Rieke Fischer, MD, Lucia Nogovà, MD, Christian Mattonet, MD, Rebecca Hein, PhD, Anne Adams, BSc, Ulrich Gerigk, MD, Wolfgang Schulte, MD, Heike Lüders, PhD, Christian Grohé, MD, Ullrich Graeven, MD, Clemens Müller-Naendrup, MD, Andreas Draube, MD, Karl-Otto Kambartel, MD, Stefan Krüger, MD, Susanne Schulze-Olden, MD, Monika Serke, MD, Walburga Engel-Riedel, MD, Britta Kaminsky, MD, Winfried Randerath, MD, Sabine Merkelbach-Bruse, PhD, Reinhard Büttner, MD, Jürgen Wolf, MD Journal of Thoracic Oncology Volume 11, Issue 1, Pages 122-127 (January 2016) DOI: 10.1016/j.jtho.2015.09.016 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A) Hematoxylin–eosin-stained micrograph of a lung adenocarcinoma with RET rearrangement. (B) Image of merged signals of a dual color, break apart fluorescent in situ hybridization analysis of a lung adenocarcinoma revealing RET rearrangement by separation of green and red signals (ZytoVision, Bremerhaven, Germany). Journal of Thoracic Oncology 2016 11, 122-127DOI: (10.1016/j.jtho.2015.09.016) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Supplemental Figure 1 Kaplan–Meier chart of overall survival (OS) of patients with stage IV disease after 34 months (SD, 18.8 months; mean ± SD, 29.3 ± 4.3 months). The median OS of patients with all stages of disease was not reached within the median follow-up period of 17 months (SD, 3.3; mean ± SD, 31.9 ± 7.2 months [data not shown]). Journal of Thoracic Oncology 2016 11, 122-127DOI: (10.1016/j.jtho.2015.09.016) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Supplemental Figure 2 Circos plot of co-occurring mutations. Connecting lines indicate frequency of co-occurrence; digits indicate chromosome numbers. Journal of Thoracic Oncology 2016 11, 122-127DOI: (10.1016/j.jtho.2015.09.016) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions